Lymphocyte-macrophage interactions in BCG-treated mice

Area of Science:

• Immunology
• Cancer Research
• Microbiology

Background:

• Bacillus Calmette-Guérin (BCG) is an immunotherapy agent.
• BCG activates macrophages, enhancing their cytotoxic activity against tumor cells.
• The dose-dependent effects of BCG on immune responses require further investigation.

Purpose of the Study:

• To investigate the effects of intravenous BCG administration on macrophage cytotoxicity and T-cell responses in mice.
• To characterize the suppressor cells induced by BCG treatment.
• To determine the role of different BCG doses in modulating immune cell activity.

Main Methods:

• Intravenous injection of varying doses of fresh living BCG into (C57Bl/6xDBA/2)Fl mice.
• Assessment of peritoneal macrophage cytotoxicity against tumor cells in vitro.
• Evaluation of spleen cell responses to T-cell mitogens (PHA and Con A).
• Characterization of suppressor cells using carbonyl iron, magnet treatment, and plastic adherence.

Main Results:

• BCG treatment activated peritoneal macrophages, increasing their tumoricidal activity.
• Maximal cytotoxic activity was observed 14 days post-BCG injection and remained stable with higher doses (3-5 mg).
• BCG induced suppressor cells, primarily macrophages, which inhibited T-cell responses.
• Higher BCG doses (3-5 mg) also led to the induction of suppressor T cells, contributing to T-cell suppression.

Conclusions:

• BCG immunotherapy effectively enhances macrophage-mediated anti-tumor activity.
• BCG administration induces a dual immune response: macrophage activation and suppressor cell induction.
• The induction of suppressor T cells at higher BCG doses may modulate the overall immune response and warrants further study.